FY2029 EPS Estimates for Personalis Cut by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Research analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for Personalis in a research note issued on Friday, February 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.33 per share for the year, down from their previous forecast of $0.35. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.40) per share.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%.

A number of other research analysts have also issued reports on the company. Lake Street Capital boosted their target price on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Needham & Company LLC dropped their target price on Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Friday, February 28th.

Personalis Stock Performance

NASDAQ:PSNL opened at $4.11 on Monday. The firm has a market cap of $362.76 million, a P/E ratio of -2.45 and a beta of 1.73. The stock’s 50 day simple moving average is $5.32 and its 200-day simple moving average is $5.02. Personalis has a 12-month low of $1.13 and a 12-month high of $7.20.

Institutional Trading of Personalis

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC boosted its stake in shares of Personalis by 154.3% in the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after buying an additional 99,671 shares in the last quarter. abrdn plc purchased a new stake in shares of Personalis in the fourth quarter valued at approximately $1,722,000. ARK Investment Management LLC boosted its position in Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after purchasing an additional 723,637 shares in the last quarter. Walleye Capital LLC purchased a new stake in Personalis during the third quarter worth $897,000. Finally, Barclays PLC boosted its position in Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after purchasing an additional 20,444 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.